Friday, January 14, 2022 9:34:35 AM
IMO, this is not the case. First of all, Dr. Fish is accomplished in many areas, but has no hands-on operating experience in any facet of a MedTech firm. He may connections that will open some device evaluation opportunities for ARTH. I would not be swayed by presumptions of his motivations for joining the Board of ARTH.
Secondly, does anyone really think that the lack of a competent advisor or Board member is the fundamental reason for the failure to date of ARTH as an operating company (vs. a penny stock investment play)? Competent wound care consultants are widely available, almost omnipresent. ARTH problems are both more fundamental and broader than the lack of a particular Board member, though an ARTH Board without members being indicted for fraud a step up for ARTH.
In any case, the numbers will tell the story. At some point, this cannot be avoided.
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM